TN10 Anti-CD3 Prevention v UK1

• Research type

  Research Study

• Full title

  ANTI-CD3 MAB (TEPLIZUMAB) FOR PREVENTION OF DIABETES IN RELATIVES AT-RISK FOR TYPE 1 DIABETES MELLITUS

• IRAS ID

  208021

• Contact name

  Penelope Bingley

• Contact email

  polly.bingley@bristol.ac.uk

• Sponsor organisation

  TrialNet Study Group

• Eudract number

  2013-002248-98

• Clinicaltrials.gov Identifier

  NCT01030861

• Clinicaltrials.gov Identifier

  IND, 102, 629

• Duration of Study in the UK

  5 years, 8 months, 1 days

• Research summary

  This study is a multicentre, double blind, randomised, placebo- controlled study to determine whether treatment of subjects at high risk for diabetes with teplizumab results in delay or prevention of clinical type 1 diabetes mellitus (T1DM).

• REC name

  South West - Central Bristol Research Ethics Committee

• REC reference

  16/SW/0316

• Date of REC Opinion

  30 Jan 2017

• REC opinion

  Further Information Favourable Opinion